MNK up +1.67% percent right now. $MNK High is at 92.67 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 1:38 PM

MNK up +1.67% percent right now. $MNK High is at 92.67 and the Low 90.80 with current volume of 302,853.

Recent News posted below.

MNK Mallinckrodt Plc Ordinary Share Recent Headline News

KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 92.81 (+1.75), IPXL: 28.89 (+0.32), KBIO: 1.94 (+0.14), MYL: 53.97 (+0.86)

Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 92.81 (+1.75), EVGN: 10.30 (-0.20), MON: 116.24 (+1.80), DNDN: 0.23 (-0.71)

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), INO: 10.87 (-0.36)

Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), BAX: 70.54 (-0.07), LLY: 67.93 (+1.33)

ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 92.81 (+1.75), SHPG: 200.44 (+1.86), UBS: 17.12 (+0.06)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.81 (+1.75), RNA: 11.87 (-0.27), AGIO: 79.65 (+7.59), CELG: 107.77 (+1.32)

Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), DNDN: 0.23 (-0.71), ICPT: 178.84 (+6.25)

Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.81 (+1.75), BDSI: 16.23 (+0.73), ISIS: 46.26 (+1.67), GSK: 45.19 (+0.28)

Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:00PM CST
Synta Pharmaceuticals Corp. (SNTA) is scheduled to report third-quarter 2014 results before the opening bell on Nov 6.
MNK: 92.81 (+1.75), SNTA: 3.12 (-0.02), INFI: 13.50 (+0.49), HSP: 56.02 (-0.30)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), PBH: 31.40 (-1.39), RPRX: 9.36 (-0.76), HSP: 56.02 (-0.30)

Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.81 (+1.75), VRTX: 116.45 (+0.52), BMRN: 86.94 (+3.03), GILD: 107.33 (+0.88), ALXN: 194.46 (+0.65)

Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), TEVA: 58.09 (+0.39)

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ARIA: 6.28 (+0.20), HSP: 56.02 (-0.30)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), HSP: 56.02 (-0.30), KERX: 16.46 (-0.27)

Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ALNY: 99.04 (+3.20), HSP: 56.02 (-0.30)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.81 (+1.75), AGN: 195.49 (-0.51), ACT: 246.41 (+0.50), BMY: 58.60 (+0.28)

Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 92.81 (+1.75), ABT: 43.91 (+0.54), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86)

Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), PFE: 30.24 (+0.32), MYL: 53.97 (+0.86)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), RDY: 55.88 (+0.16)

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:50AM CDT
Mallinckrodt, a firm in the Medical-Generic & Drug industry space, could again beat earnings, as it has witnessed a nice streak of crushing expectations.
MNK: 92.81 (+1.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...